v3.25.1
Segment Reporting
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting

Note 8 — Segment Reporting

 

As noted above, the Company’s primary focus is the commercialization of its lead product, DefenCath, indicated to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (“CVC”).

 

The Company has determined that it currently operates in a single segment - Drug Product, located in a single geographic location – the United States. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. Since the Company operates in a single segment, the measure of segment total assets and loss from operations is the same as that reported on the accompanying balance sheets as total assets, and the accompanying statement of operations as loss from operations, respectively.

 

The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). The CODM manages the Company’s business activities as a single operating and reportable segment. The CODM uses consolidated profit and loss to evaluate and measure performance against progress in its commercialization efforts and clinical trials. The following table sets forth significant segment expenses.

   March 31, 
   2025   2024 
Research and development:          
Employee expense  $1,100,387   $610,080 
Other research and development   2,092,053    227,365 
Total research and development   3,192,440    837,445 
Selling and marketing          
Employee and contracted employee expense  $2,064,124   $2,362,090 
Other selling and marketing   2,409,716    3,975,129 
Total selling and marketing expense   4,473,840    6,337,219 
General and administrative          
Employee expense  $6,842,809   $5,645,550 
Other general and administrative   2,850,573    3,065,483 
Total general and administrative expense   9,693,382    8,711,033 
Total operating expenses  $17,359,662   $15,885,697